NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales increased 4 percent and its applied science sales climbed 19 percent for the first quarter of 2008.

 

The Swiss pharmaceuticals, diagnostics, and life sciences research giant posted an overall decline in first-quarter sales of 4 percent, due to reduced demand for its influenza drug Tamiflu and the weaker US dollar. It reported revenues of 10.9 billion Swiss francs ($10.9 billion), down from CHF 11.4 million in the comparable period of 2007.